Response from FDA is completely unclear. Have zero value for investors and unfortunately we have to wait for the full protocol and Company's decision to use or not to use vision loss as an end point. On a good side, there are no negative surprises.
Ann: Initial FDA and EMA Advice on Presendin Development, page-4
-
- There are more pages in this discussion • 141 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
